Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05707871 · ClinicalTrials.gov registry record · Early Phase 1
Cardiovascular Effects of Very Low Nicotine Content Cigarettes
A Early Phase 1 study of Tobacco Use, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05707871: Recruiting Early Phase 1 study of Tobacco Use, sponsored by Wake Forest University Health Sciences.
NCT05707871 is a Early Phase 1 study of Tobacco Use that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 49 participants, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05707871, a Early Phase 1 study of Tobacco Use, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is measuring Cardiovascular effects of very low nicotine content cigarettes on daily and non-daily smokers
Primary Outcome
Change in heart rate from pre-exposure to post-exposure for the Very Low Nicotine Content Cigarettes (VLNCC)s - NRC102/103(0.5mg nicotine)
Conditions Studied
Interventions
- DRUG SPECTRUM cigarettes
- OTHER usual brand of Cigarettes
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT05707871 shows while recruiting
NCT05707871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which SPECTRUM cigarettes is the first listed.
NCT05707871 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05707871 about?
NCT05707871 is a clinical study titled "Cardiovascular Effects of Very Low Nicotine Content Cigarettes". The study is measuring Cardiovascular effects of very low nicotine content cigarettes on daily and non-daily smokers
What is the current status of trial NCT05707871?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 49 participants. The study started on 2023-04-04. Estimated completion is 2026-12.
What conditions does trial NCT05707871 study?
This clinical trial studies the following conditions: Tobacco Use.
What interventions are being tested in trial NCT05707871?
The interventions under investigation include: SPECTRUM cigarettes (DRUG), usual brand of Cigarettes (OTHER).
Who is sponsoring clinical trial NCT05707871?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05707871 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05707871's enrollment target sits among peer trials
49 56th of 76 higher than 21 of 76 other Tobacco Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
COMPLETED · Early Phase 1
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
RECRUITING · Phase 3
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI